CytomX Therapeutics, Inc.
CTMX
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 tā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.10
Price-5.49%
-$0.18
1Y
Price
Market Cap
$498.553m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-235.4%
EBITDA Margin-238.6%
Net Profit Margin-258.6%
Free Cash Flow Margin-235.4%
EBITDA Margin-238.6%
Net Profit Margin-258.6%
Free Cash Flow MarginRevenue
$35.542m
-17.7%
1y CAGR+36.4%
3y CAGR+37.9%
5y CAGREarnings
-$59.141m
-12.1%
1y CAGR+1929.4%
3y CAGR+1450.6%
5y CAGREPS
-$0.36
+10.5%
1y CAGR+1336.6%
3y CAGR+998.1%
5y CAGRBook Value
$319.944m
$359.358m
Assets$39.414m
Liabilities$2.856m
DebtDebt to Assets
0.8%
0.2x
Debt to EBITDAFree Cash Flow
-$80.194m
+16.4%
1y CAGR+4.6%
3y CAGR+5.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company